Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor

Non–small cell lung cancers (NSCLC) harbor thousands of passenger events that hide genetic drivers. Even highly recurrent events in NSCLC, such as mutations in PTEN, EGFR, KRAS, and ALK, are detected, at most, in only 30% of patients. Thus, many unidentified low-penetrant events are causing a significant portion of lung cancers. To detect low-penetrance drivers of NSCLC, a forward genetic screen was performed in mice using the Sleeping Beauty (SB) DNA transposon as a random mutagen to generate lung tumors in a Pten-deficient background. SB mutations coupled with Pten deficiency were sufficient to produce lung tumors in 29% of mice. Pten deficiency alone, without SB mutations, resulted in lung tumors in 11% of mice, whereas the rate in control mice was approximately 3%. In addition, thyroid cancer and other carcinomas, as well as the presence of bronchiolar and alveolar epithelialization, in mice deficient for Pten were also identified. Analysis of common transposon insertion sites identified 76 candidate cancer driver genes. These genes are frequently dysregulated in human lung cancers and implicate several signaling pathways. Cullin3 (Cul3), a member of a ubiquitin ligase complex that plays a role in the oxidative stress response pathway, was identified in the screen and evidence demonstrates that Cul3 functions as a tumor suppressor. Implications: This study identifies many novel candidate genetic drivers of lung cancer and demonstrates that CUL3 acts as a tumor suppressor by regulating oxidative stress. Mol Cancer Res; 13(8); 1238–47. ©2015 AACR.

[1]  Sean R. Landman,et al.  Genetic Signature of Histiocytic Sarcoma Revealed by a Sleeping Beauty Transposon Genetic Screen in Mice , 2014, PloS one.

[2]  T. Rachner,et al.  Dickkopf-1 as a mediator and novel target in malignant bone disease. , 2014, Cancer letters.

[3]  Nicholas T. Ingolia,et al.  PTEN Is a Potent Suppressor of Small Cell Lung Cancer , 2014, Molecular Cancer Research.

[4]  D. Stewart,et al.  Review Wnt Signaling Pathway in Non–small Cell Lung Cancer Overview of the Wnt Canonical (β-catenin) and Noncanonical Signaling Pathways , 2022 .

[5]  Dennis C. Friedrich,et al.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.

[6]  Edward S. Kim,et al.  Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma , 2013, Clinical Cancer Research.

[7]  K. Liu,et al.  Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216 , 2013, Clinical Cancer Research.

[8]  Donna D. Zhang,et al.  The emerging role of the Nrf2–Keap1 signaling pathway in cancer , 2013, Genes & development.

[9]  Rafael Rosell,et al.  Genetics and biomarkers in personalisation of lung cancer treatment , 2013, The Lancet.

[10]  R. Rad,et al.  Clonal Expansion Analysis of Transposon Insertions by High-Throughput Sequencing Identifies Candidate Cancer Genes in a PiggyBac Mutagenesis Screen , 2013, PloS one.

[11]  Michael J. Cronce,et al.  Type 2 alveolar cells are stem cells in adult lung. , 2013, The Journal of clinical investigation.

[12]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[13]  Thomas D. Wu,et al.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.

[14]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[15]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[16]  Hongjie Yao,et al.  Interaction of OKL38 and p53 in Regulating Mitochondrial Structure and Function , 2012, PloS one.

[17]  Michelle R. Campbell,et al.  Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha , 2012, Nucleic acids research.

[18]  M. Steinbach,et al.  New methods for finding common insertion sites and co-occurring common insertion sites in transposon- and virus-based genetic screens , 2011, Nucleic acids research.

[19]  Kevin A. T. Silverstein,et al.  TAPDANCE: An automated tool to identify and annotate transposon insertion CISs and associations between CISs from next generation sequence data , 2012, BMC Bioinformatics.

[20]  Ian M. Wilson,et al.  Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[22]  Pier Paolo Pandolfi,et al.  Subtle variations in Pten dose determine cancer susceptibility , 2010, Nature Genetics.

[23]  T. Scheetz,et al.  A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. , 2009, Cancer research.

[24]  Y. Asmann,et al.  A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer , 2009, Science.

[25]  J. Stamatoyannopoulos,et al.  Human mutation rate associated with DNA replication timing , 2009, Nature Genetics.

[26]  M. Pallardy,et al.  HMOX1 and NQO1 genes are upregulated in response to contact sensitizers in dendritic cells and THP-1 cell line: role of the Keap1/Nrf2 pathway. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  Hong Wu,et al.  Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. , 2008, Cancer research.

[28]  L. Mullenders,et al.  Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects , 2008, Cell Research.

[29]  Marcel J. T. Reinders,et al.  Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes , 2007, ISMB/ECCB.

[30]  A. Mes-Masson,et al.  Human TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates in vivo tumorigenesis , 2006, Oncogene.

[31]  Corey M. Carlson,et al.  Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse , 2005, Nature.

[32]  D. Largaespada,et al.  Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system , 2005, Nature.

[33]  P. Pandolfi,et al.  Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. , 2005, Cancer research.

[34]  B. Hogan,et al.  Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation , 2005, Development.

[35]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[36]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[37]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[38]  J. Pollack,et al.  Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins , 2004, Cancer Research.

[39]  Masayuki Yamamoto,et al.  Oxidative Stress Sensor Keap1 Functions as an Adaptor for Cul3-Based E3 Ligase To Regulate Proteasomal Degradation of Nrf2 , 2004, Molecular and Cellular Biology.

[40]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[41]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[42]  R. Cardiff,et al.  Classification of Proliferative Pulmonary Lesions of the Mouse , 2004, Cancer Research.

[43]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[44]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[45]  Soren Prag,et al.  Molecular phylogeny of the kelch-repeat superfamily reveals an expansion of BTB/kelch proteins in animals , 2003, BMC Bioinformatics.

[46]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[47]  H. Koeppen,et al.  MAGI-1: a widely expressed, alternatively spliced tight junction protein. , 2002, Experimental cell research.

[48]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[49]  Tomasz Imielinski,et al.  Database Mining: A Performance Perspective , 1993, IEEE Trans. Knowl. Data Eng..

[50]  Sushil Jajodia,et al.  Proceedings of the 1993 ACM SIGMOD international conference on Management of data , 1993, SIGMOD 1993.